1. International Agency for Research on Cancer. Available online at: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf (last accessed: June 10th 2024).
2.
Singh D, Vignat J, Lorenzoni V et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 2023; 11: E197-206.
3.
Sagae S, Toita T, Matsuura M et al. Improvement in radiation techniques for locally advanced cervical cancer during the last two decades. Int J Gynecol Cancer 2023; 33: 1295-1303.
4.
Sturdza AE, Knoth J. Image-guided brachytherapy in cervical cancer including fractionation. Int J Gynecol Cancer 2022; 32: 273-280.
5.
Georg P, Potter R, Georg D et al. Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance image-guided adaptive cervix cancer brachytherapy. Int J Radiat Oncol Biol Phys 2012; 82: 653-657.
6.
Kirchheiner K, Nout RA, Lindegaard JC et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. Radiother Oncol 2016; 118: 160-166.
7.
Westerveld H, Pötter R, Berger D et al. Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy. Radiother Oncol 2013; 107: 99-105.
8.
Raj S, Prasad RR, Swati. Incidence of vaginal toxicities in definitive chemoradiotherapy in cancer of intact cervix: A systematic review. PROSPERO 2023, CRD42023396673. Available online at: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023396673 (last accessed June 10th 2024).
9.
Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.
10.
PRISMA 2020 Checklist. Available online at: https://static1.squarespace.com/static/65b880e13b6ca75573dfe217/t/65d81881d8a48075f1fa7a3a/1708660865607/PRISMA_2020_checklist.pdf (last accessed June 10th 2024).
11.
Kumar P, Sharma DN, Kumar S et al. Pulsed-dose-rate vs. high-dose-rate intracavitary radiotherapy for locally advanced carcinoma of cervix: A prospective randomized study. Brachytherapy 2016; 15: 327-332.
12.
Gondi V, Bentzen SM, Sklenar KL et al. Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: An inter-era analysis. Int J Radiat Oncol Biol Phys 2012; 84: 973-982.
13.
Murakami N, Ando K, Murata M et al. Why not de-intensification for uterine cervical cancer? Gynecol Oncol 2021; 163: 105-109.
14.
Susko M, Craciunescu O, Meltsner S et al. Vaginal dose is associated with toxicity in image guided tandem ring or ovoid-based brachytherapy. Int J Radiat Oncol Biol Phys 2016; 94: 1099-1105.
15.
Brand AH, Bull CA, Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int J Gynecol Cancer 2006; 16: 288-293.
16.
Kirchheiner K, Nout RA, Tanderup K et al. Manifestation pattern of early-late vaginal morbidity after definitive radiation (chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study. Int J Radiation Oncol Biol Phys 2014; 89: 88e95.
17.
Westerveld H, Kirchheiner K, Nout RA et al. Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. Radiother Oncol 2022; 168: 8-15.
18.
De Felice F, Vicenzi L, Macchia G et al. Vaginal toxicity management in patients with locally advanced cervical cancer following exclusive chemoradiation-a nationwide survey on knowledge and attitudes by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gynecology Study Group. Medicina (Kaunas) 2023; 59: 385.
19.
Chopra S, Gupta S, Kannan S et al. Late toxicity after adjuvant conventional radiation versus image-guided intensity-modulated radiotherapy for cervical cancer (PARCER): A randomized controlled trial. J Clin Oncol 2021; 39: 3682-3692.
20.
Ranjan N, Chopra S, Mangaj A et al. Months and severity score (MOSES) in a phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials. eClinicalMedicine 2022; 47: 101390.
21.
Rai B, Dhanireddy B, Patel FD et al. Vaginal dose, toxicity and sexual outcomes in patients of cervical cancer undergoing image based brachytherapy. Asian Pac J Cancer Prev 2014; 15: 3619-3623.
22.
Tharavichitkul E, Jayavasti R, Galalae RM et al. The associations for vaginal point doses of vaginal stenosis in image-guided brachytherapy. J Cancer Ther 2014; 2014.
23.
Kaidar-Person O, Abdah-Bortnyak R, Amit A et al. Tolerance of the vaginal vault to high-dose rate brachytherapy and concomitant chemo-pelvic irradiation: Long-term perspective. Rep Pract Oncol Radiother 2014; 19: 56-61.
24.
Okonogi N, Murakami N, Ando K et al. An Asian multi-national, multi-institutional, retrospective study on image-guided brachytherapy in cervical adenocarcinoma and adenosquamous carcinoma. J Contemp Brachytherapy 2022; 14: 311-320.
25.
Dankulchai P, Harn-Utairasmee P, Prasartseree T et al. Vaginal 11-point and volumetric dose related to late vaginal complications in patients with cervical cancer treated with external beam radiotherapy and image-guided adaptive brachytherapy. Radiother Oncol 2022; 174: 77-86.
26.
Fidarova EF, Burger D, Schussler S et al. Dose volume parameter D2cc does not correlate with vaginal side effects in individual patients with cervical cancer treated within a defined treatment protocol with very high brachytherapy doses. Radiother Oncol 2010; 97: 76-79.
27.
Conway JL, Felder S, Tang J et al. Long-term patient-reported distress in locally advanced cervical cancer patients treated with definitive chemoradiation. Clin Transl Radiat Oncol 2020; 23: 1-8.
28.
Tse V, Shiarli AM, Aldridge S et al. A review of practice and outcomes of external beam radiotherapy treatment with concurrent chemotherapy followed by MRI-assisted intracavitary brachytherapy for locally advanced cervix cancer. Brachytherapy 2016; 15: S93.
29.
Atasever Akkas E, Altundag MB. Long-term clinical outcome and dosimetric comparison of tandem and ring versus tandem and ovoids intracavitary application in cervical cancer. J BUON 2021; 26: 698-706.
30.
Tharavichitkul E, Muangwong P, Chakrabandhu S et al. Comparison of clinical outcomes achieved with image-guided adaptive brachytherapy for cervix cancer using CT or transabdominal ultrasound. Brachytherapy 2021; 20: 543-549.
31.
Ruanla J, Muangwong P, Kittidachanan K et al. The association of vagina equivalent dose in 2Gy fraction (EQD(2)) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT. Brachytherapy 2022; 21: 658-667.
32.
Misra S, Lal P, Kumar ES et al. Comparative assessment of late toxicity in patients of carcinoma cervix treated by radiotherapy versus chemo-radiotherapy – Minimum 5 years follow up. Cancer Treat Res Commun 2018; 14: 30-36.
33.
Alam N, Akram M, Siddiqui SA, Hussain MB. Interdigitated versus sequential high-dose-rate intracavitary brachytherapy with external beam radiotherapy in locally advanced carcinoma cervix. J Cancer Res Ther 2019; 15: 1254-1259.
34.
Sadiq S, Shahid A, Masood M et al. Acute side effects with high dose rate computed tomography-guided three-dimensional brachytherapy in carcinoma cervix. J Coll Physicians Surg Pak 2020; 30: 638-642.
35.
Tharavichitkul E, Tippanya D, Jayavasti R et al. Two-year results of transabdominal ultrasound-guided brachytherapy for cervical cancer. Brachytherapy 2015; 14: 238-244.
36.
Saibishkumar EP, Patel FD, Sharma SC. Evaluation of late toxicities of patients with carcinoma of the cervix treated with radical radiotherapy: an audit from India. Clin Oncol R Coll Radiol 2006; 18: 30-37.
